Most pages listing tesamorelin benefits mix one proven effect with five borrowed ones. The proven effect is visceral fat: down 15.2% over 26 weeks in a trial of 412 adults with HIV lipodystrophy. Everything else on the list traces back somewhere weaker.
The short answer. Tesamorelin: The only FDA-approved benefit is visceral fat reduction in HIV-associated lipodystrophy, approved in 2010.
- Phase 3 trials in 412 adults cut visceral fat 15.2% over 26 weeks while placebo rose 5.0%. The effect reversed after stopping.
- Liver fat and immune activation markers also improved, but only in studies of people with HIV and fatty liver disease.
- The 2025 Ellis trial in 73 patients cut waist circumference 2.7 cm but did not improve cognition.
Tesamorelin has one FDA-approved use. That is belly fat in HIV lipodystrophy, since 2010. Pivotal trials cut visceral fat 15–18% in 26 weeks. Later studies found less liver fat and calmer immune markers. A 73-patient trial in 2025 missed on cognition. Anti-aging and muscle claims have no trial behind them.
What tesamorelin actually does in the body
Tesamorelin is a stabilized copy of growth-hormone-releasing hormone. It does not supply growth hormone. It tells the pituitary to release its own, in the body's normal pulses.
That distinction matters for every benefit claim downstream. The effects you can trace are the effects of raising IGF-1 and pulsatile growth hormone inside a physiological range. They are not the effects of injected growth hormone.
A 2021 review in Drug Testing and Analysis describes the whole class of GHRH analogs this way, and notes that the substitution at the N-terminus is what protects tesamorelin from the enzyme that clears native GHRH within minutes.
The full molecular picture sits in the stabilized GHRH mechanism page.
The one benefit with Phase 3 evidence: visceral fat
This is the claim that earned the label. Two randomized placebo-controlled Phase 3 trials measured visceral adipose tissue by CT scan in adults with HIV-associated lipodystrophy.
Visceral fat fell 15.2% on drug and rose 5.0% on placebo across 26 weeks. Across the program the reduction ran 15–18%. The FDA approved it in 2010.
- The target is deep fat, not subcutaneous fat. The trials did not show a change in the fat under the skin.
- The effect reverses. When dosing stopped, the fat came back.
- Nothing measured appearance. The outcome was a CT-measured area in square centimeters.
- It held up on modern HIV regimens. A 2024 sub-analysis of 38 patients on integrase inhibitors, published by Russo and colleagues in AIDS, confirmed the effect.
The numbers and their limits are laid out in tesamorelin before and after and the HIV lipodystrophy page.
Every trial that produced these figures enrolled people with HIV. There is no equivalent trial in healthy adults, at any body weight.
Liver fat and immune markers: real, and still in the same population
The second-strongest claim is liver fat. Tesamorelin was tested in people with HIV and nonalcoholic fatty liver disease, and the liver endpoints moved.
Liver fat fraction fell −4.2% on drug against −0.5% on placebo in that work. Fourman and colleagues then went further and sequenced liver tissue before and after, in JCI Insight in 2020, to see which pathways changed.
Tesamorelin may have beneficial effects on hepatic inflammation and fibrogenesis, beyond a simple reduction in hepatic fat content.
Fourman et al., JCI Insight, 2020A parallel paper by Stanley and colleagues in Clinical Infectious Diseases in 2021 found circulating markers of immune activation fell alongside the hepatic pathway changes. A 2021 targeted proteomic study in Scientific Reports mapped the same response.
This is genuinely good mechanistic work. It is also small, and it is entirely inside HIV-associated liver disease. A 2021 review in Drug Design, Development and Therapy places tesamorelin in a crowded NASH landscape where nothing had yet cleared a definitive endpoint.
Tesamorelin
The compound discussed here, supplied as a research compound with a certificate of analysis matched to the lot.
Fat quality, dorsocervical fat, and where the data thins
Two smaller studies are worth naming because they are frequently cited as if they were headline findings.
Lake and colleagues reported in AIDS in 2021 that tesamorelin improved fat quality, measured by CT attenuation, independent of how much fat quantity changed. Rahman and colleagues looked at whether people with dorsocervical fat pads responded differently, in a 61 study participants analysis published in 2022.
| Claimed benefit | Best evidence | Population |
|---|---|---|
| Visceral fat reduction | Two Phase 3 RCTs, 412 adults | HIV lipodystrophy |
| Reduced liver fat | Randomized trial plus liver biopsy work | HIV with NAFLD |
| Lower immune activation | Substudy, Clinical Infectious Diseases 2021 | HIV with NAFLD |
| Better fat quality | CT attenuation analysis, AIDS 2021 | HIV lipodystrophy |
| Cognitive improvement | Mixed; 2025 trial did not improve cognition | HIV, and one aging pilot |
| Muscle or injury repair | No controlled trial | — |
| Healthy aging, longevity | Review-level speculation only | — |
Fourman and Grinspoon's 2022 clinical review in JCEM treats tesamorelin as a lipodystrophy tool. That is the framing the evidence supports.
The benefits that failed or were never tested
Name the absence, because this is where most of the marketing lives.
Cognition. The 2025 Ellis trial in the Journal of Infectious Diseases ran 6 months in 73 people with HIV and abdominal obesity. Waist fell 2.7 cm against standard care. Cognition did not improve. An earlier 2012 pilot in older adults with mild cognitive impairment did find small gains, from a single center. Both sides are covered in tesamorelin cognition and aging.
Muscle, tendon, athletic performance. A 2026 Sports Medicine review by Mendias and Awan surveys approved and unapproved peptides for musculoskeletal injury and finds the evidence base for the unapproved ones thin. Tesamorelin has no controlled musculoskeletal trial. It is banned by WADA under S2.
Longevity. A 2026 Frontiers in Aging review by Mavrych and colleagues discusses therapeutic peptides in gerontology at the mechanism level. Mechanism is not outcome.
Growth hormone secretagogues remain an area of active investigation for body composition, but their role outside of approved indications is not established.
Paraphrasing Sinha et al., Translational Andrology and Urology, 2020- Beta-cell protection comes from MR-409, a different GHRH agonist, in streptozotocin-treated rodents (PNAS, 2023).
- Glioma activity comes from sermorelin, not tesamorelin (Annals of Translational Medicine, 2021). See the tesamorelin vs sermorelin comparison.
- Reversal of diet-induced metabolic damage comes from a 2024 PLOS ONE rat study on cART regimens.
Those three findings are real. None of them is a tesamorelin benefit in humans.
What this means if you are comparing sources
The prescription product is Egrifta and Egrifta SV. Without insurance it runs $3,500–5,000 a month in the US, and insurance covers it only for the HIV indication.
Research vials are a different category entirely. They are not the approved drug, and the FDA status of Egrifta is not the status of a research vial. There are also side effects on the label, including injection-site reactions and glucose effects, covered in tesamorelin side effects.
If you are evaluating a vendor, the document to ask for is a third-party certificate of analysis with identity and purity. How to read a COA explains what a real one contains. The complete guide covers formulations and the three label doses.
Tesamorelin
Research-use-only material, sold by the vial with batch documentation. Check the certificate of analysis against the batch you receive.
What to know now
- The only FDA-approved benefit is visceral fat reduction in HIV-associated lipodystrophy, approved in 2010.
- Phase 3 trials in 412 adults cut visceral fat 15.2% over 26 weeks while placebo rose 5.0%. The effect reversed after stopping.
- Liver fat and immune activation markers also improved, but only in studies of people with HIV and fatty liver disease.
- The 2025 Ellis trial in 73 patients cut waist circumference 2.7 cm but did not improve cognition.
- Muscle repair, athletic performance and longevity claims have no controlled human trial behind them.
- Several cited findings belong to other peptides: MR-409 in rodent beta cells, sermorelin in glioma.
What we're watching
Watch whether any sponsor runs a tesamorelin trial in adults without HIV. Every efficacy figure in circulation comes from an HIV population, and nobody has tested whether it transfers.
Frequently asked questions
What is tesamorelin approved for?
One thing. Reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. The FDA approved it in 2010, and a more concentrated form in 2019. The label covers nothing else.
Does tesamorelin help with weight loss in people without HIV?
No trial has answered that. Every controlled efficacy study enrolled people with HIV. The trials also measured visceral fat area on CT, not body weight, and subcutaneous fat did not change.
Does tesamorelin improve memory?
The evidence is split and the most recent answer was no. The 2025 Ellis trial in the Journal of Infectious Diseases ran 6 months in 73 people with HIV and abdominal obesity and found no cognitive improvement. A small 2012 pilot in older adults with mild cognitive impairment did report gains from a single center.
Is tesamorelin good for building muscle?
There is no controlled trial of tesamorelin for muscle or tendon outcomes. A 2026 Sports Medicine review by Mendias and Awan examined peptides marketed for musculoskeletal injury and athletic performance and found the evidence for unapproved compounds limited. Tesamorelin is also banned by WADA under class S2.
How much does tesamorelin cost?
The prescription product runs $3,500 to $5,000 a month in the US without insurance, and insurance generally covers it only for the HIV indication.
Do the benefits last after stopping?
Not in the pivotal data. When dosing stopped in the Phase 3 program, visceral fat returned. The trials did not test any maintenance approach.
References
- Russo, S. C., Ockene, M. W., Arpante, A. K., et al. (2024). Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS, 38(12), 1758–1764. https://doi.org/10.1097/QAD.0000000000003965
- Fourman, L. T., Billingsley, J. M., Agyapong, G., et al. (2020). Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI Insight, 5(16). https://doi.org/10.1172/jci.insight.140134
- Ellis, R. J., Vaida, F., Hu, K., et al. (2025). Effects of tesamorelin on neurocognitive impairment in persons with HIV and abdominal obesity. Journal of Infectious Diseases, 231(5), 1230–1238. https://doi.org/10.1093/infdis/jiaf012
- Stanley, T. L., Fourman, L. T., Wong, L. P., et al. (2021). Growth hormone releasing hormone reduces circulating markers of immune activation in parallel with effects on hepatic immune pathways in individuals with HIV-infection and nonalcoholic fatty liver disease. Clinical Infectious Diseases, 73(4), 621–630. https://doi.org/10.1093/cid/ciab019
- Fourman, L. T., Stanley, T. L., Billingsley, J. M., et al. (2021). Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach. Scientific Reports, 11(1), 10485. https://doi.org/10.1038/s41598-021-89966-y
- Lake, J. E., La, K., Erlandson, K. M., et al. (2021). Tesamorelin improves fat quality independent of changes in fat quantity. AIDS, 35(9), 1395–1402. https://doi.org/10.1097/QAD.0000000000002897
- Rahman, F., McLaughlin, T., Mesquita, P., et al. (2022). Effect of tesamorelin in people with HIV with and without dorsocervical fat. Journal of Clinical and Translational Science, 7(1), e40. https://doi.org/10.1017/cts.2022.515
- Fourman, L. T., & Grinspoon, S. K. (2022). Approach to the patient with lipodystrophy. Journal of Clinical Endocrinology and Metabolism, 107(6), 1714–1726. https://doi.org/10.1210/clinem/dgac079
- Gattu, A. K., & Fourman, L. T. (2025). Metabolic dysfunction-associated steatotic liver disease in people with HIV. Current Opinion in HIV and AIDS, 20(4), 350–358. https://doi.org/10.1097/COH.0000000000000952
- Fraile, J. M., Palliyil, S., Barelle, C., Porter, A. J., & Kovaleva, M. (2021). Non-alcoholic steatohepatitis (NASH) - a review of a crowded clinical landscape. Drug Design, Development and Therapy, 15, 3997–4009. https://doi.org/10.2147/DDDT.S315724
- Chege, P. M., Sokoya, T., Mwaura, B., et al. (2024). Tesamorelin reverses obesogenic metabolic effects of cART regimens combined with low-protein high-calorie diets in rats. PLOS ONE, 19(3), e0298752. https://doi.org/10.1371/journal.pone.0298752
- Mendias, C. L., & Awan, T. M. (2026). Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance. Sports Medicine. https://doi.org/10.1007/s40279-026-02437-0
- Mavrych, V., Shypilova, I., & Bolgova, O. (2026). Therapeutic peptides in gerontology: Mechanisms and applications for healthy aging. Frontiers in Aging, 7, 1790247. https://doi.org/10.3389/fragi.2026.1790247
- Memdouh, S., Gavrilović, I., Ng, K., Cowan, D., & Abbate, V. (2021). Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Testing and Analysis, 13(11–12), 1871–1887. https://doi.org/10.1002/dta.3183